LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,485
تعداد دریافت فایل اصل مقاله11,291,274
Hou, Meiling, Wang, Xiaodong, Lu, Jike, Guo, Xun, Ding, Cong, Liang, Taotao, Ji, Zhenyu, Xie, Peng, Liu, Xin, Kang, Qiaozhen. (1398). TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response. سامانه مدیریت نشریات علمی, 17(1), 14-25. doi: 10.22034/iji.2020.80291
Meiling Hou; Xiaodong Wang; Jike Lu; Xun Guo; Cong Ding; Taotao Liang; Zhenyu Ji; Peng Xie; Xin Liu; Qiaozhen Kang. "TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response". سامانه مدیریت نشریات علمی, 17, 1, 1398, 14-25. doi: 10.22034/iji.2020.80291
Hou, Meiling, Wang, Xiaodong, Lu, Jike, Guo, Xun, Ding, Cong, Liang, Taotao, Ji, Zhenyu, Xie, Peng, Liu, Xin, Kang, Qiaozhen. (1398). 'TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response', سامانه مدیریت نشریات علمی, 17(1), pp. 14-25. doi: 10.22034/iji.2020.80291
Hou, Meiling, Wang, Xiaodong, Lu, Jike, Guo, Xun, Ding, Cong, Liang, Taotao, Ji, Zhenyu, Xie, Peng, Liu, Xin, Kang, Qiaozhen. TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response. سامانه مدیریت نشریات علمی, 1398; 17(1): 14-25. doi: 10.22034/iji.2020.80291

TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response

Iranian Journal of Immunology
مقاله 2، دوره 17، شماره 1، خرداد 2020، صفحه 14-25    اصل مقاله (879.51 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22034/iji.2020.80291
نویسندگان
Meiling Hou1؛ Xiaodong Wang1؛ Jike Lu1؛ Xun Guo1؛ Cong Ding1؛ Taotao Liang1؛ Zhenyu Ji2؛ Peng Xie3؛ Xin Liu* 1؛ Qiaozhen Kang* 1
1School of Life Sciences, Zhengzhou University, Zhengzhou, PR China
2Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China
3Zhengzhou Xinzhiyi Biotechnology Co., Zhengzhou, PR China
چکیده
Background: Melanoma is a common and malignant cutaneous tumor, which is responsible for a large proportion of skin cancer deaths. Dendritic cell (DC)-based vaccines have achieved positive results in the treatment of melanoma because of their ability to induce cytotoxic response to facilitate tumor elimination. Objective: To improve the efficacy of dendritic cell-based vaccines by the adjuvant activity of Helicobacter pylori neutrophil activating protein (HP-NAP), which is a virulence factor of Helicobacter pylori, has been proved as a TLR agonist with effective immunomodulatory activity. Methods: The recombinant HP-NAP (rHP-NAP) was expressed by using prokaryotic expression system. Dendritic cells (DCs) were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4. After treating with rHP-NAP, the maturation of DCs and dendritic cell-based vaccine were assayed by using flow cytometry and qRT-PCR. The activation and proliferation of T cells were measured by FCM, ELISA and MTT methods. The tumor specific cytotoxic response to resistant B16F10 was detected by using lactate dehydrogenase-release assay and qRT-PCR. Results: The recombinant HP-NAP (rHP-NAP), prepared from E. coli prokaryotic expression system, was able to significantly promote the maturation of dendritic cell-based vaccine loaded with tumor cell lysate (TCL) of B16F10 (DC-B16F10-TCL). Furthermore, it effectively induced the activation and proliferation of T cells and tumor specific cytotoxic response to resistant B16F10 melanoma tumor cells. Conclusion: These results suggested that rHP-NAP possesses the potential for use as an adjuvant of dendritic cell-based vaccine in anti-melanoma treatment.
کلیدواژه‌ها
Cytotoxic Response؛ Dendritic Cell-Based Vaccine؛ Melanoma؛ rHP-NAP
سایر فایل های مرتبط با مقاله
آمار
تعداد مشاهده مقاله: 1,917
تعداد دریافت فایل اصل مقاله: 1,355


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب